Things to check before participating in DSANJ Bio Conference

Jan.28 – Feb.3 , 2026

私は以下の内容を了解し、DSANJ Bio Conference （以下「本カンファレンス」とします）に参加します。
※□はチェック（☑）をお願いいたします。チェック方法： □の上の✓マークを□の中にドラッグして移動させてください。

I understand the following and agree to participate in DSANJ Bio Conference.
* Please check the boxes (□) for each confirmation. How to check: Drag the ✓ symbol from beside the □ into the □ box.

☑	私は、以下本カンファレンスの参加資格を満たすことを確認しました。 <参加資格> （１）　国内外の大学、研究機関、スタートアップ若しくはこれらに所属する研究者であること （２）　創薬研究成果の製薬企業等への移転や共同研究について検討している、検討する可能性を有する者であること I confirm that I meet the following eligibility requirements for participating in this conference. <Eligibility requirements for participation> (1) Researchers affiliated with a university, research institute, or start-up in Japan and abroad (2) Researchers who are considering, or may consider, technology transfer to a pharmaceutical company or joint research with such a company
☑	私は、本カンファレンスに提供する資料に秘密情報を含めないことを確認しました。 I assure that the materials I am providing to this conference contain no confidential information.
☑	私は、本カンファレンス資料が専用ページ上に掲載され、参加企業の閲覧に供されることを確認しました。 I accept that the materials for this conference will be posted on a dedicated page and made available for inspection by participating companies.

DSANJ
Drug Seeds Alliance Network Japan

Things to check before participating in DSANJ Bio Conference

Jan.28 – Feb.3 , 2026

☑	私は、本カンファレンスにおいて、秘密情報を開示しないことを確認しました。 I assure that I will not disclose any confidential information at this conference.
☑	私は、提出資料および本カンファレンスの内容を、DSANJ事務局が主催者および参加企業と共有する場合があることを確認しました。 I accept that the DSANJ Admin Office may share information about the content of this conference and the submitted materials with the organizers and participating companies.
☑	私は、本カンファレンスの結果（企業からのフィードバック）を面談企業各社からではなく、DSANJ事務局から受領することを確認しました。 I understand that I will receive the results of this conference (feedback from companies) from the DSANJ Admin Office, not from the companies I meet with.
☑	本カンファレンスの参加にあたって費用は発生せず、また、参加企業との連携（共同研究等）に至った際にも成功報酬は一切発生しないことを確認しました。 I understand that no fee is required to participate in this conference, and that no success fee will be paid in the event of collaboration (joint research, etc.) with participating companies.
☑	本カンファレンスを契機に発生したトラブル・損害等について、主催・共催・後援・協力の各機関・団体は、これらの各機関・団体に故意または重過失に基づく場合を除き、一切の責任を負わないものとすることを確認しました。 I understand that the organizing, co-organizing, supporting, and cooperating organizations/groups will not be held responsible for any trouble or damages incurred as a result of this conference, except in cases where such trouble or damages are due to intentional or gross negligence on the part of those organizations/groups.

Contact Information for DSANJ Bio Conference

Jan.28 – Feb.3 , 2026

※日本語をご使用の方へ：すべての項目（日本語・英語の両方）をご記入ください。
For English users:Please fill in only the fields with English labels.
※参加者が多い場合は、枠を追加して作成をよろしくお願いいたします。
If you have a large number of participants, please add slots.
※本情報は、DSANJ Bio Conference参加企業と共有し、参加企業が会期中あるいは前後でやり取りする際に利用いたします。
This information will be shared with the DSANJ Bio Conference participating companies, and will be used for communication during and after the conference.

●Principal Investigator（研究代表者）

Name	Taro Daisyo
名前	大商　太郎
Organization	Drug Seeds Alliance Network Japan University
所属機関	創薬シーズ基盤技術アライアンスネットワーク大学
Department/Title	School of Medicine, Department of Endocrinology and Metabolic Medicine, professor
部門・肩書	医学系研究科 内分泌・代謝内科学　教授
E-mail	xxxxxx@osaka.cci.or.jp

DSANJ
Drug Seeds Alliance Network Japan

Contact Information for DSANJ Bio Conference

Jan.28 – Feb.3 , 2026

●Co-researcher（分担研究者）

Name	Kazuo Osaka
名前	大阪　和夫
Organization	Drug Seeds Alliance Network Japan University
所属機関	創薬シーズ基盤技術アライアンスネットワーク大学
Department/Title	School of Medicine, Department of Endocrinology and Metabolic Medicine Associate, Professor
部門・肩書	医学系研究科　内分泌・代謝内科学　准教授
E-mail	xxxxxx2@osaka.cci.or.jp

Name	Hanako　Yodogawa
名前	淀川　花子
Organization	DSANJ Medical University
所属機関	DSANJ医科大学
Department/Title	Clinical Endocrinology and Metabolism, Professor
部門・肩書	臨床内分泌・代謝学　教授
E-mail	xxxxxx@osakmed.cci.or.jp

DSANJ
Drug Seeds Alliance Network Japan

Contact Information for DSANJ Bio Conference

Jan.28 – Feb.3 , 2026

●External liaison administrator（外部連携窓口）

Name	Tsugiko Syoko
名前	商工　次子
Organization	Drug Seeds Alliance Network Japan University
所属機関	創薬シーズ基盤技術アライアンスネットワーク大学
Department/Title	Organization for Society-Academia Collaboration
部門・肩書	産学連携共創機構　URA
E-mail	xxxxxx3@osaka.cci.or.jp

Name	
名前	
Organization	
所属機関	
Department/Title	
部門・肩書	
E-mail	

DSANJ
Drug Seeds Alliance Network Japan

Proposal materials for DSANJ Bio Conference

Jan.28 – Feb.3 , 2026

本資料はDSANJ Bio Conferenceでのご提案を検討されている研究者向けのサンプルです。

本資料内の情報は全てフィクションであり、架空のストーリーをもとに作成しております。

※目的外の利用は禁止いたします。

First-in-class therapeutic strategy targeting XXX in pancreatic cancer

- Presentation Subtitle (English) -

XXXを標的とした新規膵臓がん治療薬

- サブタイトル（日本語） -

Osaka Chamber of Commerce and Industry

大阪商工会議所

Professor Daisyo Taro Ph.D.

教授　大商　太郎

Executive summary

The objective of this research is to treat the disease by targeting its underlying mechanism.

This research targets a novel upstream regulator in pancreatic cancer, aiming to address a significant unmet medical need.

Data from in vitro and in vivo studies confirm its efficacy.

Identified compounds demonstrate >100-fold stronger apoptotic activity in vitro and ~60% tumor regression in vivo.

Summary of "Advantages of this study over competing studies"

- Structure-activity relationship (SAR) studies support pharmacophore development.
- Potential for companion diagnostic development based on biomarker P protein.

Collaboration with pharmaceutical companies is sought for development support and further advancement of this research

Seeking partnership for preclinical studies and diagnostic validation.

Background to study (1)

- Pancreatic cancer remains one of the most lethal malignancies with a 5-year survival rate under 10%.





- This project targets a novel upstream regulator to provide a first-in-class therapeutic approach addressing this critical unmet medical need.

Summary of study (1)

Pancreatic cancer regression by inhibition of XXX

Compound A, an inhibitor of XXX, induced apoptosis in a concentration-dependent manner in a patient-derived pancreatic cancer cell line held in our laboratory.

We synthesized 200 derivatives from compound A in collaboration with a synthesis laboratory, and further searched for compounds with higher activity and safety. As a result, we obtained compounds X and Y, which are about 100 times more active than compound A, as well as the structure-activity relationship of the compounds.





Summary of study (2)

Effect of compounds X and Y on a pancreatic cancer cell line

When X µmol/L of compounds were added to cells from a pancreatic cancer cell line and the cell numbers were compared after 24 hours, compounds X and Y exerted apoptotic effects more than 100 times greater than that of compound A.

When 10 X µmol/L, 10 times higher than X µmol/L, of the compounds were added to normal cells, the cytotoxicity of compounds X and Y was lower than that of compound A.





Summary of study (3)

Effect in murine xenograft models

Cells from a pancreatic cancer cell line were labeled and transplanted into immunodeficient mice. After the cells were colonized (X cm^3), compounds X and Y were administered intravenously at Y mg/kg. The photo shows the size of the tumors taken during live imaging 1 week after administration.

While the tumor in the control group increased in size, the tumor in the treated groups regressed (to 40% of the original size).

In addition, no significant side effects were observed after administration, and therefore the drug is expected to be safe.



Con X Y

Advantage of this study over competing studies (1)

- At this stage, a dramatic regression of pancreatic cancer has been noted, there are no anticancer drugs that focus on protein P, and synergy with existing drugs is also expected.
- At this stage, we have also analyzed the structure-activity relationship of compounds related to candidate compounds X and Y, which are based on compound A, and we expect to discover more active compounds.
- We have developed an assay system to screen inhibitors of XXX, with which new compounds can be screened from libraries of companies.
- At this stage, no significant side effects have been observed for compounds X or Y, and therefore they are assumed to be safe.
- Protein P in pancreatic juice can be used as a biomarker for early detection of pancreatic cancer.







Plan for practical application and collaboration with companies (1)

1) Goal and its plan for research and/or development

- Development of a new pancreatic cancer drug with compounds X and Y as lead compounds
- Development of a diagnostic agent for early detection of pancreatic cancer using protein P as a marker



Plan for practical application and collaboration with companies (2)

2) Tasks of this proposal to success

- Further investigation into the safety of compounds X and Y
- Search for more effective XXX inhibitors

Plan for practical application and collaboration with companies (3)

3) Division of roles

Role of Proposer

- Clarification of the detailed mechanism of action
- Study of the effect on other types of cancer

Role of this business partner(s)

- Search for more active compounds by library screening
- Optimization of the above compounds

Reference （ Patents / Background materials ）

1) Patent and its status

Patent application 201X XXXXXXX
Marker for early detection of pancreatic cancer
Osaka Taro, Osaka Chamber of Commerce and Industry

Patent application 201X XXXXXXX
New anticancer drug
Osaka Taro, Osaka Chamber of Commerce and Industry

2) Key paper and / or

Science Repo ...

Related Information

Key word to this proposal

- Pancreatic cancer
- Protein P
- XXX
- Compound B

Potential target disease on this proposal

Other cancer types with increased levels of protein P